Lundbeck beats profits expectations on cost cuts; Hospira sales up to $1B; Novartis lobbies FDA on biosim names;

@FiercePharma: Trending now: Novartis eyes animal health sale as first slim-down move: Bloomberg. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Here's yesterday afternoon's Vivus Q3 earnings call transcript. More | Follow @CarlyHFierce

> Copenhagen-based Lundbeck raised its profit expectations as generic competition eased in the third quarter and cost-cutting benefits kicked in. Report

> Hospira ($HSP) posted a profit of $29 million on sales of just over $1 billion for the third quarter as it continues to spend money on fixing quality problems flagged by the FDA. Report

> Novartis ($NVS) asked the FDA to ignore calls for unique names on biosimilar versions of biotech drugs, in favor of names that would make biosims more easily substitutable for branded products. Report

> Sanofi ($SNY) priced a €1 billion bond issue with a maturity date in 2023. Report

> Hungary's state asset manager said it would offer €900 million in bonds relating to shares in the domestic drugmaker Richter, of which it owns 25.24%. Report

> The Indian government may revise its list of essential drugs while it's still in the process of implementing new fixed prices for the products currently included. Report

> The French drugmaker Ipsen announced a share buyback plan covering 800,000 shares. Report

Medical Device News

@FierceMedDev: Supreme Court to decide on Medtronic, Boston Scientific patent fight by June. Story | Follow @FierceMedDev

@MarkHFierce: Check out our latest issue of FierceDiagnostics--lots of good stuff and just sent out. Newsletter | Follow @MarkHFierce

> New PillCam approvals accelerate Given Imaging's revenue gains. More

> Medtronic looks to widen its renal denervation lead with latest trial. Story

> Direct Flow snags up to $50M to push heart valve in crowded market. Article

Biotech News

@FierceBiotech: Morningstar analyst ranks the top 11 pharma giants' prospects, putting GSK on top. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Novartis to chop 371 jobs, shutter research center in global R&D shakeup. Story | Follow @JohnCFierce

@DamianFierce: Medtronic looks to widen its renal denervation lead with latest trial. Article | Follow @DamianFierce

@EmilyMFierce: This is worth a listen: Teaching Science Through Hip Hop. More | Follow @EmilyMFierce

> GlaxoSmithKline picks discovery-stage winners in R&D Star Search. More

> FDA puts a clamp on Curis cancer drug program after patient dies of liver failure. Story

> Karyopharm joins biotech's fall IPO parade with $109M haul. Article

Drug Delivery News

@MichaelGFierce: Gold nanoparticles first to deliver RNA to brain tumors. More | Follow @MichaelGFierce

> Langer lab makes synthetic 'good cholesterol' for cardiovascular drug delivery. Item

> IBM uses hydrogel to prolong delivery of Roche's Herceptin. More

> Platinum drug delivery method snuffs cancer's power source. Article

> Novo Nordisk wins FDA approval for two automated-dose insulin pens. News

> Study: Arrowhead's hep B RNAi drug could offer 'functional cure'. Report

Diagnostics News

> Cancer Dx test maker Veracyte launches successful IPO. Item

> Ariosa defeats Sequenom in prenatal testing patent battle. More

> Illumina, Natera, Ariosa tests gain contracts with CA's prenatal Dx program. Story

> AutoGenomics pulls IPO plans and mulls possible private offering instead. Article

> PerkinElmer to sell Transgenomic molecular Dx oncology tests overseas. Report

> Alere's new HIV test could gain momentum from Affordable Care Act. News

And Finally... Mind over matter? Apparently. Telling yourself you feel great during exercise may actually make you feel better. Report (sub. req.)

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.